Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy

다국어 초록 (Multilingual Abstract)

Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated.
Methods Eighty-five patients received perampanel between March 2016 and August 2016.
Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months.
Results Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively).
Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.

참고문헌 (Reference)

1 Heyman E, "Tolerability and efficacy of perampanel in children with refractory epilepsy" 59 : 441-444, 2017

2 Fisher RS, "The new classification of seizures by the international league against epilepsy 2017" 17 : 48-, 2017

3 Patsalos PN, "The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist" 56 : 12-27, 2015

4 Rogawski MA, "Revisiting AMPA receptors as an antiepileptic drug target" 11 : 56-63, 2011

5 Krauss GL, "Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures" 78 : 1408-1415, 2012

6 Villanueva V, "Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures" 127 : 126-134, 2016

7 Trinka E, "Perampanel for focal epilepsy: insights from early clinical experience" 133 : 160-172, 2016

8 Vazquez B, "Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures" 56 : e90-e94, 2015

9 Schalock RL, "Intellectual disability: definition, classification, and systems of supports"

10 Franconi F, "Gender differences in drug responses" 55 : 81-95, 2007

11 Steinhoff BJ, "First clinical experiences with perampanel--the Kork experience in 74 patients" 55 (55): 16-18, 2014

12 French JA, "Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305" 54 : 117-125, 2013

13 Biro A, "Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences" 46 : 110-116, 2015

14 De Liso P, "Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: an Italian observational multicenter study" 127 : 93-100, 2016

15 Gidal BE, "Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures" 54 : 1490-1497, 2013

16 Shah E, "Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study" 34 : 1-5, 2016

17 French JA, "Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304" 79 : 589-596, 2012

18 Steinhoff BJ, "A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria" 108 : 986-988, 2014